Generic Name and Formulations:
Insulin aspart (rDNA origin) 100 Units/mL; soln for SC inj, continuous subcutaneous insulin infusion (CSII), IV infusion; contains zinc, m-cresol.
Indications for NOVOLOG:
For SC inj, CSII, or IV infusion: see full labeling. Onset approx ≤15 mins, peak approx 1–3hrs, duration approx 3–5hrs.
<2yrs: not recommended. 2–4yrs: use SC inj only. ≥4yrs: may use SC inj or CSII: see full labeling. Onset approx ≤15 mins, peak approx 1–3hrs, duration approx 3–5hrs.
During episodes of hypoglycemia.
Do not reuse or share pens, cartridges between patients; or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. CSII: Do not mix with other insulins or diluent when pump is used.
Hypoglycemia, hypokalemia, local inj site reactions, lipodystrophy, rash, pruritus, edema, sodium retention, weight gain; hypersensitivity and allergic reactions.
Vials (10mL)—1; FlexPen (3mL prefilled syringe)—5; PenFill (3mL cartridges)—5; NovoPen Echo (inj device, uses PenFill cartridges)—1
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally